Loren Joseph to Mutation
This is a "connection" page, showing publications Loren Joseph has written about Mutation.
Connection Strength
0.306
-
Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study. Clin Lymphoma Myeloma Leuk. 2019 07; 19(7):431-440.e13.
Score: 0.073
-
Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. Lung Cancer. 2017 04; 106:17-21.
Score: 0.062
-
The clinical utility of molecular genetic cancer profiling. Expert Rev Mol Diagn. 2016 08; 16(8):827-38.
Score: 0.060
-
Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma. Leukemia. 2015 Oct; 29(10):2113-6.
Score: 0.055
-
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8.
Score: 0.012
-
Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease. J Clin Pathol. 2011 Jan; 64(1):16-24.
Score: 0.010
-
Identification of histologically distinct conventional adenomas that arise predominately in patients with sessile serrated adenomas. Am J Surg Pathol. 2010 Mar; 34(3):355-63.
Score: 0.010
-
Inducible heat shock protein 70 prevents multifocal flat dysplastic lesions and invasive tumors in an inflammatory model of colon cancer. Carcinogenesis. 2009 Jan; 30(1):175-82.
Score: 0.009
-
Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis. Cancer Res. 2007 Jan 15; 67(2):827-35.
Score: 0.008
-
Epidermal growth factor receptor signaling is up-regulated in human colonic aberrant crypt foci. Cancer Res. 2006 Jun 01; 66(11):5656-64.
Score: 0.007